<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330238</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2008-005351-14</org_study_id>
    <nct_id>NCT01330238</nct_id>
  </id_info>
  <brief_title>The Efficacy of Zoledronic Acid in Modic Changes-related Low Back Pain (LBP)</brief_title>
  <official_title>Phase 2 Study of the Efficacy of Zoledronic Acid in Low Back Pain Related to Vertebral Endplate Signal Changes, the So-called Modic Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modic changes are associated with low back pain (LBP) both in clinical and general
      population-based samples. Type I changes are regarded as more likely to be painful than type
      II changes. Several studies suggest that type I changes are inflammatory in nature.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      So far, no treatment exists for LBP due to Modic changes. Bisphosphonates could be effective
      in this specific low back disorder through two mechanisms: 1) they could consolidate
      vertebral bodies thereby improving the tolerance for mechanical load and 2) they could
      diminish inflammation as observed recently in case of ibandronate in an experimental model.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low back pain (VAS)</measure>
    <time_frame>0, 1, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (RAND-36)</measure>
    <time_frame>0, 1, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flexibility of the lumbar spine</measure>
    <time_frame>0, 1, 12 months</time_frame>
    <description>Modified Schober measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sick leaves</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Patient-reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic phenotype</measure>
    <time_frame>0, 12 months</time_frame>
    <description>Change in proportion and size of type I changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability (Oswestry)</measure>
    <time_frame>0, 1, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single infusion of 5 mg zoledronic acid I.V.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single infusion of 100 ml isotonic NaCl-solution I.V.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid vs. placebo</intervention_name>
    <description>Single infusion of zoledronic acid or placebo</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Aclasta</other_name>
    <other_name>Zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 years old

          -  low back pain for more than 3 months

          -  Modic type I or II change in lumbar magnetic resonance imaging

          -  Intensity of low back pain at least 6 on 10-cm VAS or Oswestry disability score at
             least 30%

        Exclusion Criteria:

          -  premenopausal female patients with possibility of pregnancy

          -  patients with calculated creatinine clearance of less than 40 ml/min

          -  patients with hypocalcemia

          -  patients with known hypersensitivity to zoledronic acid or other bisphosphonates or
             ingredients of the infusional product

          -  patients with red flags symptoms

          -  patients with nerve root impingement

          -  patients with willingness for early retirement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaro Karppinen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katri Koivisto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eero Kyllönen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaj Sundqvist, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaakko Niinimäki, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osmo Tervonen, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Clinical Sciences, Department of Physical and Rehabilitation Medicine, University of Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Katri Koivisto</investigator_full_name>
    <investigator_title>Specialist in Physical and Rehabilitation Medicine</investigator_title>
  </responsible_party>
  <keyword>Low back pain</keyword>
  <keyword>Modic changes</keyword>
  <keyword>Vertebral endplate signal changes</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>Bisphosphonates</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

